Immunotherapies in Rheumatologic Disorders
Immunotherapies in Rheumatologic Disorders
复制标题
DOI：
10.1016/j.mcna.2012.04.003
复制
发表时间：
2012-05-01
影响因子：
5.9
通讯作者：
Ranatunga, Sriya K. M.
中科院分区：
文献类型：
--
作者：
Miller, Anne V.;Ranatunga, Sriya K. M.
在过去的几十年里，风湿病学的重点是了解和对抗免疫失调的免疫性自身免疫性疾病与风湿性表现。旧的治疗方法虽然有效但知之甚少，正在重新审视，并产生其功效背后的免疫调节机制。新疗法，即“生物制剂”，是针对特定免疫缺陷和失衡而量身定制的药物。本文讨论了目前的标准和生物免疫治疗的风湿性疾病，我们目前的理解，其机制与功能障碍被认为是目前在主要的自身免疫综合征，特别是类风湿性关节炎和系统性红斑狼疮。
Over the past several decades, rheumatology has directed its focus to understanding and countering the immune dysregulation underlying autoimmune diseases with rheumatologic manifestations. Older therapies, effective though poorly understood, are being scrutinized anew and are yielding the immune-modulating mechanisms behind their efficacy. New therapies, the "biologics," are drugs tailored to address specific immune defects and imbalances. This article discusses the current standard and biologic immunotherapies of the rheumatic diseases, correlating our current understanding of their mechanisms with dysfunctions believed to be present in the major autoimmune syndromes, especially rheumatoid arthritis and systemic lupus erythematosus.